A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Recruiting · NCT06760364 · Interventional (participants receive a specific treatment) · Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
View the official record on ClinicalTrials.gov →Interventions studied
CHT102
What this trial is about
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Ability to understand and sign a written informed consent documen；
- At the date of signing ICF, 18 \~70 years old, male or female；
- Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
- Positive mesothelin expression;
- At least one measurable lesion at baseline per RECIST version 1.1；
- The expected survival time is more than 12 weeks;
- ECOG 0-1 points;
- Adequate organ functions.
Where it is running
1 location listed.
- Tianjin Medical University Cancer Institute & Hospital - Tianjin, China